

Stephen T Barclay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7379734/publications.pdf>

Version: 2024-02-01

21
papers

506
citations

933264

10
h-index

794469

19
g-index

22
all docs

22
docs citations

22
times ranked

953
citing authors

#	ARTICLE	IF	CITATIONS
1	Competing Risk Bias in Prognostic Models Predicting Hepatocellular Carcinoma Occurrence: Impact on Clinical Decision-making. , 2022, 1, 129-136.		1
2	Effect of Hepatocellular Carcinoma Surveillance Programmes on Overall Survival in a Mixed Cirrhotic UK Population: A Prospective, Longitudinal Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2770.	1.0	8
3	The Value of Quantitative Faecal Immunochemical Testing as a Prioritisation Tool for the Endoscopic Investigation of Patients With Iron Deficiency. <i>Frontiers in Medicine</i> , 2021, 8, 700753.	1.2	4
4	Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1635-1642.	1.0	12
5	The association between deprivation and the incidence and survival of patients with hepatocellular carcinoma in the West of Scotland. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1427-1433.	1.4	2
6	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. <i>JHEP Reports</i> , 2021, 3, 100384.	2.6	10
7	Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-90.	0.9	0
8	Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 270-280.	1.0	27
9	The reported "clear cut" time association between interferon-free treatment and HCC is anything but clear cut. <i>Journal of Hepatology</i> , 2020, 72, 1034-1035.	1.8	1
10	Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 371-375.	1.0	7
11	Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 809-818.	3.7	51
12	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	1.8	158
13	Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. <i>Advances in Therapy</i> , 2020, 37, 4033-4042.	1.3	18
14	Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype. <i>Journal of Viral Hepatitis</i> , 2020, 27, 996-1002.	1.0	7
15	Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. <i>Gut</i> , 2020, 69, 2223-2231.	6.1	17
16	The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. <i>Journal of Hepatology</i> , 2018, 68, 646-654.	1.8	82
17	Insights into frequent asthma exacerbations from a primary care perspective and the implications of UK National Review of Asthma Deaths recommendations. <i>Npj Primary Care Respiratory Medicine</i> , 2018, 28, 35.	1.1	20
18	Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. <i>Drug and Alcohol Dependence</i> , 2016, 165, 53-60.	1.6	43

#	ARTICLE	IF	CITATIONS
19	What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?. <i>Journal of Hepatology</i> , 2015, 62, 262-268.	1.8	10
20	Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model. <i>Journal of Hepatology</i> , 2014, 60, 1118-1126.	1.8	18
21	Massive hemorrhage from a pulmonary veinâ€“esophageal fistula: a late complication of Histoacryl glue injection. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 1037-1038.	0.5	10